Pharmaceutical company Selkirk Pharma acquiring land for campus expansion on the West Plains

<p><p>The Spokane-based pharmaceutical company Selkirk Pharma has announced it’s entering a purchase and sale agreement to acquire more than 10 acres of land adjacent to its 145,000-square-foot facility currently under construction at 9111 W. Granite Ave.</p></p><p><p>The land acquisition will expand Selkirk Pharma’s campus to a total of 27 acres and add “critically-needed capacity” for manufacturing commercial and clinical trial drugs, the company said in a news release.</p></p><p><p>The campus will include three separate buildings with “industry leading technology” designed for contract manufacturing of injectable pharmaceuticals, including vaccines and biological therapeutics, according to the company.</p></p><p><p>“Spokane is a special place to live, work, and invest,” Selkirk Pharma CEO Patrick Haffey said in a statement. “We are grateful to be here and plan to make a series of long-term investments in this community over the coming years.”</p></p><p><p>Haffey did not respond to a request for comment on additional details of the expansion.</p></p><p><p>Spokane County Assessor’s Office records show that Granite Investments LLC, whose principal is Richard Vandervert, owns the more than 10-acre site adjacent to Selkirk Pharma’s campus.</p></p><p><p>Selkirk Pharma was founded in 2018 by a team of physicians and pharmaceutical leaders. The company has an office at 821 W. First Ave. in downtown Spokane.</p></p><p><p>Selkirk Pharma and its partners have invested more than $90 million in the West Plains manufacturing campus and will announce additional investments at a later date, according to the news release.</p></p><p><p>The company has 35 employees and is recruiting workers to support operation of its first plant, which is slated for completion in March.</p></p><p><p>Some of those positions include business systems professionals, project engineers, scientists as well as quality assurance, technical documentation and validation specialists, according to the company’s website.</p></p><p><p>Selkirk Pharma’s campus, when complete, is expected to employ more than 750 scientists, engineers and operations personnel, according to the company.</p></p>